Record UK biotech investment, new COVID-19 variant-busting collaboration
UK Bioindustry Association (BIA) chief executive Steve Bates yesterday released an update on the biotech sector, including on investment and COVID-19 developments.
New data published by the BIA and Clarivate reveals that UK biotech companies raised a record £2.8 billion ($3.94 billion) in equity finance in 2020. The science of success: UK biotech in 2020 marks the best year for biotech investments we have ever recorded and shows that since 2012 investment has increased by over 1000%, he said.
Underscoring this finance success story last week was the news that GW Pharmaceutical (Nasdaq: GWPH) is to be acquired by the USA’s Jazz Pharmaceuticals (Nasdaq: JAZZ) for $7.2 billion – the largest acquisition of a UK biotech company on record.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze